Compositions and methods related to graft versus host disease and treatments thereof
Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In particular, the present invention relates to compositions and methods for inhibition of graft rejection and promotion of graft survival. Thus, the invention relates to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection and conditions commonly associated with graft rejection. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease and inducers of other alpha1-antitrypsin activities.
1. A method for reducing risk of onset of graft versus host disease (GvHD) in a human subject having a non-organ transplant and at risk of developing GvHD, comprising administering to the human subject a composition comprising alpha-1 antitrypsin (AAT) or a recombinant molecule thereof, and a pharmaceutically acceptable excipient, and reducing the risk of developing GvHD in the human subject.
2. The method of claim 1 , further comprising administering one or more anti-rejection agent, anti-inflammatory agent, immunosuppressive agent, immunomodulatory agent, anti-microbial agent, anti-viral or combination thereof to the human subject.
3. The method of claim 1 , wherein the GvHD is attributed to a stem cell or bone marrow implant in the human subject.
4. The method of claim 3 , wherein the GvHD is attributed to bone marrow implantation and the human subject is administered the composition following the bone marrow implantation.
5. The method of claim 1 , wherein the composition is administered to the human subject at a dose of about 0.1 mg/kg to about 100 mg/kg.
6. A method for reducing risk of onset of graft versus host disease (GvHD) in a non-organ transplant human subject, comprising, administering to the non-organ transplant human subject at risk of developing GvHD, a composition consisting essentially of alpha-1 antitrypsin (AAT) or recombinant molecule thereof, and a pharmaceutically acceptable excipient, to reduce the risk of developing GvHD in the human subject.
7. The method of claim 6 , wherein the composition is administered after non-organ transplantation to reduce incidence of GvHD in the human subject as compared to a control human subject not receiving the composition.
8. The method of claim 1 , wherein the AAT or the recombinant molecule thereof comprises a full-length AAT polypeptide and the AAT polypeptide is part of a fusion polypeptide.
9. The method of claim 8 , wherein the fusion polypeptide comprises the full-length AAT polypeptide fused to an immunoglobulin constant region.
10. The method of claim 9 , wherein the immunoglobulin constant region comprises an IgG1 constant region.